Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine

Abstract

Colorectal cancer is the third most common and the fourth most lethal cancer worldwide. In most of cases, patients are diagnosed at an advanced or even metastatic stage, thus explaining the high mortality. The lack of proper clinical tests and the complicated procedures currently used for detecting this cancer, as well as for predicting the response to treatment and the outcome of a patient’s resistance in guiding clinical practice, are key elements driving the search for biomarkers. In the present overview, the different biomarkers (diagnostic, prognostic, treatment resistance) discovered through proteomics studies in various colorectal cancer study models (blood, stool, biopsies), including the different proteomic techniques used for the discovery of these biomarkers, are reviewed, as well as the various tests used in clinical practice and those currently in clinical phase. These studies define the limits and perspectives related to proteomic biomarker research for personalised medicine in colorectal cancer.

Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures

“…The predictive biomarkers were applied to indicate the response from a specific treatment and to guide the decision-making process. Recently, the increasing number of therapeutic drugs (chemotherapy, immunotherapy, and target therapy) used for CRC make it necessary to discover some response parameters and monitoring evaluations [24]. Unfortunately, we did not obtain detailed information about the treatment protocols for our recruited CRC patients, and thus it is worthy to further investigate whether MAOB can be a predictive biomarker for a specific treatment in CRC.…”

Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research

“…The prospection of new predictive biomarkers is crucial to the evolution of the management of patients with colorectal cancer in the near future, and proteomics represent a powerful strategy for the discovery and implementation of personalized approaches. The increasing number of chemotherapy and immunotherapy drugs and the emergence of target therapies make it necessary to discover some response parameters and monitoring evaluations (45, 46).…”

In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers

“…Colorectal cancer (CRC) is the third most common cancer worldwide with an estimated incidence of 1.9 million new cases per year worldwide [1–3]. It is one of the leading causes accounting for cancer death [4, 5]. The high mortality in CRC patients is largely attributed to its late diagnosis made at advanced stage when CRC metastases had developed [6].…”